These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 7611194)

  • 1. Octreotide-associated biliary tract dysfunction and gallstone formation: pathophysiology and management.
    Redfern JS; Fortuner WJ
    Am J Gastroenterol; 1995 Jul; 90(7):1042-52. PubMed ID: 7611194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gallstones during octreotide therapy.
    Dowling RH; Hussaini SH; Murphy GM; Besser GM; Wass JA
    Metabolism; 1992 Sep; 41(9 Suppl 2):22-33. PubMed ID: 1355588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein E4 genotype and gallbladder motility influence speed of gallstone clearance and risk of recurrence after extracorporeal shock-wave lithotripsy.
    Portincasa P; van Erpecum KJ; van De Meeberg PC; Dallinga-Thie GM; de Bruin TW; van Berge-Henegouwen GP
    Hepatology; 1996 Sep; 24(3):580-7. PubMed ID: 8781328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tauroursodeoxycholic acid, ursodeoxycholic acid and gallbladder motility in gallstone patients and healthy subjects.
    Portincasa P; DiCiaula A; Palmieri V; Velardi A; Van Berge-Henegouwen GP; Palasciano G
    Ital J Gastroenterol; 1996; 28(2):111-3. PubMed ID: 8782006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gallbladder function in acromegalic patients taking long-term octreotide: evidence of rebound hypermotility on cessation of treatment.
    Rhodes M; James RA; Bird M; Clayton B; Kendall-Taylor P; Lennard TW
    Scand J Gastroenterol; 1992; 27(2):115-8. PubMed ID: 1561523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of continuous subcutaneous infusion of octreotide on gallstone formation in acromegalic patients.
    Tauber JP; Poncet MF; Harris AG; Barthel HR; Simonetta-Chateauneuf C; Buscail L; Bayard F
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3262-6. PubMed ID: 7593435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Why does somatostatin cause gallstones?
    Ahrendt SA; McGuire GE; Pitt HA; Lillemoe KD
    Am J Surg; 1991 Jan; 161(1):177-82; discussion 182-3. PubMed ID: 1987853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on the pathogenesis and treatment of cholesterol gallstones.
    Portincasa P; van de Meeberg P; van Erpecum KJ; Palasciano G; VanBerge-Henegouwen GP
    Scand J Gastroenterol Suppl; 1997; 223():60-9. PubMed ID: 9200309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Causes and management of recurrent biliary pain after successful nonoperative gallstone treatment.
    Wehrmann T; Marek S; Hanisch E; Lembcke B; Caspary WF
    Am J Gastroenterol; 1997 Jan; 92(1):132-8. PubMed ID: 8995953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholesterol crystallization in human gallbladder bile: relation to gallstone number, bile composition, and apolipoprotein E4 isoform.
    Van Erpecum KJ; Van Berge-henegouwen GP; Eckhardt ER; Portincasa P; Van De Heijning BJ; Dallinga-Thie GM; Groen AK
    Hepatology; 1998 Jun; 27(6):1508-16. PubMed ID: 9620320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of gallstone formation by sphincterotomy in the prairie dog: reversal by atropine.
    Hutton SW; Sievert CE; Vennes JA; Duane WC
    Gastroenterology; 1982 Jun; 82(6):1308-13. PubMed ID: 7067954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiology of cholesterol gallstone disease.
    Méndez-Sánchez N; Cárdenas-Vázquez R; Ponciano-Rodríguez G; Uribe M
    Arch Med Res; 1996; 27(4):433-41. PubMed ID: 8987174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients.
    Shi YF; Zhu XF; Harris AG; Zhang JX; Dai Q
    J Clin Endocrinol Metab; 1993 Jan; 76(1):32-7. PubMed ID: 8421099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of hypolipidemic treatment on the composition of bile and the risk or cholesterol gallstone disease].
    Zák A; Zeman M; Hrubant K; Vecka M; Tvrzická E
    Cas Lek Cesk; 2007; 146(1):24-34. PubMed ID: 17310581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gallstones during octreotide therapy.
    Dowling RH; Hussaini SH; Murphy GM; Wass JA
    Digestion; 1993; 54 Suppl 1():107-20. PubMed ID: 8103009
    [No Abstract]   [Full Text] [Related]  

  • 16. Sluggish small bowel motility is involved in determining increased biliary deoxycholic acid in cholesterol gallstone patients.
    Azzaroli F; Mazzella G; Mazzeo C; Simoni P; Festi D; Colecchia A; Montagnani M; Martino C; Villanova N; Roda A; Roda E
    Am J Gastroenterol; 1999 Sep; 94(9):2453-9. PubMed ID: 10484008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of tegaserod on bile composition and hepatic secretion in Richardson ground squirrels on an enriched cholesterol diet.
    Mathison R; Shaffer E; Pfannkuche HJ; Earnest D
    Lipids Health Dis; 2006 Jun; 5():15. PubMed ID: 16792807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic bile versus gallbladder bile: a comparison of protein and lipid concentration and composition in cholesterol gallstone patients.
    Keulemans YC; Mok KS; de Wit LT; Gouma DJ; Groen AK
    Hepatology; 1998 Jul; 28(1):11-6. PubMed ID: 9657090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cholecystokinin-1 receptor antagonist devazepide increases cholesterol cholelithogenesis in mice.
    Wang HH; Portincasa P; Wang DQ
    Eur J Clin Invest; 2016 Feb; 46(2):158-69. PubMed ID: 26683129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered gallbladder bile acidification with long-term total parenteral nutrition.
    Dawes LG; Greiner M; Joehl RJ
    J Surg Res; 1999 Jan; 81(1):21-6. PubMed ID: 9889052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.